Cargando…

Modifying the Non-muscle Invasive Bladder Cancer Immune Microenvironment for Optimal Therapeutic Response

It is now well-recognized that the tumor microenvironment (TME) is not only a key regulator of cancer progression but also plays a crucial role in cancer treatment responses. Recently, several high-profile publications have demonstrated the importance of particular immune parameters and cell types t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Annels, Nicola E., Simpson, Guy R., Pandha, Hardev
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7040074/ https://www.ncbi.nlm.nih.gov/pubmed/32133299 http://dx.doi.org/10.3389/fonc.2020.00175

Ejemplares similares

Oncolytic immunotherapy for the treatment of non-muscle invasive bladder cancer using intravesical coxsackievirus A21
por: Annels, Nicola E, et al.
Publicado: (2015)

Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate Tumors
por: Annels, Nicola E., et al.
Publicado: (2020)

Bacillus Calmette–Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer
por: Su, Fei, et al.
Publicado: (2022)

A Specific Blood Signature Reveals Higher Levels of S100A12: A Potential Bladder Cancer Diagnostic Biomarker Along With Urinary Engrailed-2 Protein Detection
por: Elamin, Ayssar A., et al.
Publicado: (2020)

Oncolytic Immunotherapy for Bladder Cancer Using Coxsackie A21 Virus
por: Annels, Nicola E., et al.
Publicado: (2018)

Metabolomics of Non-muscle Invasive Bladder Cancer: Biomarkers for Early Detection of Bladder Cancer
por: Cheng, Xiangming, et al.
Publicado: (2018)

Non-muscle invasive bladder cancer biomarkers beyond morphology
por: De Carlo, Camilla, et al.
Publicado: (2022)

Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13
por: Gabitass, Rachel F., et al.
Publicado: (2011)

Multiplatform Biomarker Discovery for Bladder Cancer Recurrence Diagnosis
por: De Paoli, Marine, et al.
Publicado: (2016)

Modified immunoscore improves the prediction of progression-free survival in patients with non-muscle-invasive bladder cancer: A digital pathology study
por: Bieri, Uwe, et al.
Publicado: (2022)

HOX and PBX gene dysregulation as a therapeutic target in glioblastoma multiforme
por: Arunachalam, Einthavy, et al.
Publicado: (2022)

Global research trends in non-muscle invasive bladder cancer: Bibliometric and visualized analysis
por: Deng, Sheng, et al.
Publicado: (2022)

Precise diagnosis and treatment of non-muscle invasive bladder cancer - A clinical perspective
por: Yang, Yongjun, et al.
Publicado: (2023)

A review of the biology and therapeutic implications of cancer-associated fibroblasts (CAFs) in muscle-invasive bladder cancer
por: Burley, Amy, et al.
Publicado: (2022)

Prognostic Value of Immune-Related Genes in the Tumor Microenvironment of Bladder Cancer
por: Li, Faping, et al.
Publicado: (2020)

Muscle-invasive angiosarcoma of the urinary bladder: Case report
por: Madiraju, Srigita, et al.
Publicado: (2023)

Trimodality Therapy for Bladder Preservation in the Elderly Population with Invasive Bladder Cancer
por: Turgeon, Guy-Anne, et al.
Publicado: (2014)

Circulating Tumor DNA Analyses Predict Disease Recurrence in Non-Muscle-Invasive Bladder Cancer
por: Zhang, Jinghua, et al.
Publicado: (2021)

Serum metabolites as early detection markers of non-muscle invasive bladder cancer in Chinese patients
por: Zhao, Yi, et al.
Publicado: (2023)

An MRI-based radiomics nomogram in predicting histologic grade of non-muscle-invasive bladder cancer
por: Li, Longchao, et al.
Publicado: (2023)

Classification of Muscle-Invasive Bladder Cancer Based on Immunogenomic Profiling
por: Zhou, Xianghong, et al.
Publicado: (2020)

Muscle-invasive bladder cancer following radiotherapy for prostate adenocarcinoma
por: Barnett, Jack, et al.
Publicado: (2020)

Knowledge of and Compliance With Guidelines in the Management of Non-Muscle-Invasive Bladder Cancer: A Survey of Chinese Urologists
por: Wang, Dan-Qi, et al.
Publicado: (2021)

Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs
por: Grabe-Heyne, Kristin, et al.
Publicado: (2023)

Editorial: Tumor microenvironment in bladder cancer
por: Kusmartsev, Sergei, et al.
Publicado: (2023)

Dysregulation of the Immune Microenvironment Contributes to Malignant Progression and Has Prognostic Value in Bladder Cancer
por: Zheng, Zongtai, et al.
Publicado: (2020)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
por: Miller, Katie Joanna, et al.
Publicado: (2023)

Therapeutic Targeting of Tumor Cells and Tumor Immune Microenvironment Vulnerabilities
por: Kalyanaraman, Balaraman, et al.
Publicado: (2022)

Comprehensive analysis of cuproptosis-related genes on bladder cancer prognosis, tumor microenvironment invasion, and drug sensitivity
por: Wang, Honglei, et al.
Publicado: (2023)

Efficacy and safety of photodynamic therapy for non–muscle-invasive bladder cancer: a systematic review and meta-analysis
por: Li, Haitao, et al.
Publicado: (2023)

Engrailed-2 (EN2) – a novel biomarker in epithelial ovarian cancer
por: McGrath, Sophie Elena, et al.
Publicado: (2018)

Cost‐effectiveness of surveillance schedules in older adults with non‐muscle‐invasive bladder cancer
por: Heijnsdijk, Eveline A.M., et al.
Publicado: (2018)

M6A Classification Combined With Tumor Microenvironment Immune Characteristics Analysis of Bladder Cancer
por: Zhu, Huili, et al.
Publicado: (2021)

Body composition as a predictor of oncological outcome in patients with non-muscle-invasive bladder cancer receiving intravesical instillation after transurethral resection of bladder tumor
por: Huang, Liang-Kang, et al.
Publicado: (2023)

Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis
por: Liu, Kang, et al.
Publicado: (2020)

Urethral fistula and perineal collection during intravesical treatment for non-muscle invasive bladder cancer – A rare complication
por: Ong, Katherine, et al.
Publicado: (2022)

The relationship between inflammatory response markers and the prognosis of non-muscle invasive bladder cancer and the development of a nomogram model
por: Yi, Xinping, et al.
Publicado: (2023)

Neoadjuvant Treatment in Muscle-Invasive Bladder Cancer: From the Beginning to the Latest Developments
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Impact of the time of surgical delay on survival in patients with muscle-invasive bladder cancer
por: Li, Shuaishuai, et al.
Publicado: (2022)

The role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies
por: Wang, Danting, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vod9mvh5httnen73ide1mkq3ka